Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for RilzabrutinibGlobeNewsWire • 11/24/20
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.GlobeNewsWire • 09/22/20
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related DiseaseGlobeNewsWire • 09/17/20
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?PRNewsWire • 09/12/20
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YINPRNewsWire • 09/10/20
PRINCIPIA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Principia Biopharma Inc. - PRNBBusiness Wire • 08/20/20
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Principia Biopharma Inc. to SanofiNewsfile Corp • 08/17/20
STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Principia Biopharma Inc. - PRNBPRNewsWire • 08/17/20
Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia BiopharmaBusiness Wire • 08/17/20
Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment EffortsInvestors Business Daily • 08/17/20
Analysts Estimate Principia Biopharma Inc. (PRNB) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/06/20
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple SclerosisGlobeNewsWire • 06/23/20